Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era

Autor: Prusila, R. E. (Roosa E. I.), Sorigue, M. (Marc), Jauhiainen, J. (Jyrki), Mercadal, S. (Santiago), Postila, A. (Aleksi), Salmi, P. (Petteri), Tanhua, T. (Taru), Tikkanen, S. (Susanna), Kakko, S. (Sakari), Kuitunen, H. (Hanne), Pollari, M. (Marjukka), Nystrand, I. (Ilja), Kuusisto, M. E. (Milla E. L.), Vasala, K. (Kaija), Jantunen, E. (Esa), Korkeila, E. (Eija), Karihtala, P. (Peeter), Sancho, J. (Juan‐Manuel), Turpeenniemi‐Hujanen, T. (Taina), Kuittinen, O. (Outi)

Publikováno v: British Journal of Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Follicular lymphoma (FL) is the most common indolent lymphoma. Currently there are many comparable treatment options available for FL. When selecting the most optimal therapy it is important to consider possible late effects of the treatment as well

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::207fb7a1e225966ac134639fc2db5fd4
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3184